company background image
6606

New Horizon Health SEHK:6606 Stock Report

Last Price

HK$24.75

Market Cap

HK$10.6b

7D

63.0%

1Y

-69.1%

Updated

26 Jun, 2022

Data

Company Financials +
6606 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

6606 Stock Overview

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China.

New Horizon Health Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for New Horizon Health
Historical stock prices
Current Share PriceHK$24.75
52 Week HighHK$84.00
52 Week LowHK$14.00
Beta0
1 Month Change52.78%
3 Month Change18.42%
1 Year Change-69.06%
3 Year Changen/a
5 Year Changen/a
Change since IPO-70.54%

Recent News & Updates

Mar 23
News Flash: Analysts Just Made A Captivating Upgrade To Their New Horizon Health Limited (HKG:6606) Forecasts

News Flash: Analysts Just Made A Captivating Upgrade To Their New Horizon Health Limited (HKG:6606) Forecasts

New Horizon Health Limited ( HKG:6606 ) shareholders will have a reason to smile today, with the analysts making...

Jan 19
Need To Know: Analysts Are Much More Bullish On New Horizon Health Limited (HKG:6606) Revenues

Need To Know: Analysts Are Much More Bullish On New Horizon Health Limited (HKG:6606) Revenues

Celebrations may be in order for New Horizon Health Limited ( HKG:6606 ) shareholders, with the analysts delivering a...

Shareholder Returns

6606HK HealthcareHK Market
7D63.0%8.6%2.1%
1Y-69.1%-66.7%-23.3%

Return vs Industry: 6606 underperformed the Hong Kong Healthcare industry which returned -66.7% over the past year.

Return vs Market: 6606 underperformed the Hong Kong Market which returned -23.3% over the past year.

Price Volatility

Is 6606's price volatile compared to industry and market?
6606 volatility
6606 Average Weekly Movement12.1%
Healthcare Industry Average Movement8.4%
Market Average Movement7.0%
10% most volatile stocks in HK Market13.8%
10% least volatile stocks in HK Market3.3%

Stable Share Price: 6606 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: 6606's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2015804Yeqing Zhuhttps://ir.newhorizonbio.com

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.

New Horizon Health Fundamentals Summary

How do New Horizon Health's earnings and revenue compare to its market cap?
6606 fundamental statistics
Market CapCN¥9.06b
Earnings (TTM)-CN¥3.09b
Revenue (TTM)CN¥212.76m

42.6x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6606 income statement (TTM)
RevenueCN¥212.76m
Cost of RevenueCN¥58.12m
Gross ProfitCN¥154.65m
Other ExpensesCN¥3.24b
Earnings-CN¥3.09b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-7.18
Gross Margin72.68%
Net Profit Margin-1,450.14%
Debt/Equity Ratio3.7%

How did 6606 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 6606 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6606?

Other financial metrics that can be useful for relative valuation.

6606 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue34.6x
Enterprise Value/EBITDA-26.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 6606's PS Ratio compare to its peers?

6606 PS Ratio vs Peers
The above table shows the PS ratio for 6606 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average5.4x

Price-To-Sales vs Peers: 6606 is expensive based on its Price-To-Sales Ratio (42.6x) compared to the peer average (5.4x).


Price to Earnings Ratio vs Industry

How does 6606's PE Ratio compare vs other companies in the Hong Kong Healthcare Industry?

Price-To-Sales vs Industry: 6606 is expensive based on its Price-To-Sales Ratio (42.6x) compared to the Hong Kong Healthcare industry average (1.7x)


Price to Sales Ratio vs Fair Ratio

What is 6606's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6606 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio42.6x
Fair PS Ratio19.7x

Price-To-Sales vs Fair Ratio: 6606 is expensive based on its Price-To-Sales Ratio (42.6x) compared to the estimated Fair Price-To-Sales Ratio (19.7x).


Share Price vs Fair Value

What is the Fair Price of 6606 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6606's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6606's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6606's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is New Horizon Health forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


85.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6606 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6606 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6606 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6606's revenue (40.8% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).

High Growth Revenue: 6606's revenue (40.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6606's Return on Equity is forecast to be low in 3 years time (4.7%).


Discover growth companies

Past Performance

How has New Horizon Health performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-291.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: 6606 is currently unprofitable.

Growing Profit Margin: 6606 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 6606's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 6606's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6606 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (34.8%).


Return on Equity

High ROE: 6606 has a negative Return on Equity (-145.08%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is New Horizon Health's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6606's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥193.4M).

Long Term Liabilities: 6606's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥33.9M).


Debt to Equity History and Analysis

Debt Level: 6606 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 6606's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6606 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6606 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is New Horizon Health current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6606's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6606's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6606's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6606's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6606 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Yeqing Zhu (49 yo)

4yrs

Tenure

Mr. Yeqing Zhu is the Chief Executive Officer of New Horizon Health Ltd. since June 7, 2018. Mr. Zhu is an Executive Director of New Horizon Health Ltd.since October 9, 2020 and served as its Director fro...


Leadership Team

Experienced Management: 6606's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: 6606's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

New Horizon Health Limited's employee growth, exchange listings and data sources


Key Information

  • Name: New Horizon Health Limited
  • Ticker: 6606
  • Exchange: SEHK
  • Founded: 2015
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: HK$10.636b
  • Shares outstanding: 429.74m
  • Website: https://ir.newhorizonbio.com

Number of Employees


Location

  • New Horizon Health Limited
  • T1 Building
  • 13th Floor
  • Hangzhou
  • Zhejiang Province
  • 310052
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.